Roche announced that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known to play an important role in disea
read more » Discuss Add this link to...Bury Add to:
| Bookmarks